Last updated: February 21, 2026
Description of the Case
The lawsuit involves Acorda Therapeutics Inc. accusing Aurobindo Pharma Ltd. of patent infringement related to multiple patents covering formulations and methods of treating Multiple Sclerosis (MS) with Ampyra (dalfampridine). The case commenced in the District of Delaware in 2014.
Background
Acorda holds patents covering extended-release formulations of dalfampidine as a treatment for MS-related walking impairment. Aurobindo, a generic pharmaceutical manufacturer, sought FDA approval for a generic version of Ampyra in 2013, asserting that the patents were invalid or non-infringing.
Patent Claims
The patents asserted include US patent numbers:
- 8,349,755: Covers specific extended-release formulations.
- 8,585,509: Method claims for treating MS symptoms with dalfampidine.
Aurobindo’s FDA Approval
In 2013, Aurobindo filed an Abbreviated New Drug Application (ANDA), claiming that its product did not infringe and/or was invalid.
Litigation Timeline and Key Events
| Date |
Event |
Details |
| 2014 |
Complaint filed |
Acorda files suit for patent infringement in Delaware. |
| 2014 |
Temporary Restraining Order (TRO) |
Acorda seeks to prevent Aurobindo from launching generic Ampyra pending trial. |
| 2015 |
Settlement negotiations |
Parties engage in settlement discussions. |
| 2016 |
Court trial |
Bench trial commences, focusing on patent validity and infringement. |
| 2017 |
Decision |
The court finds the patents invalid and not infringed. |
| 2018 |
Appeal |
Acorda appeals the ruling. |
| 2019 |
Court affirms |
The Federal Circuit affirms the invalidity decision. |
| 2020 |
Market impact |
Aurobindo launches generic Ampyra, subject to ongoing patent litigation outcomes. |
Court Rulings and Outcomes
Patent Validity
The court initially found the patents invalid on grounds of obviousness and lack of enablement, citing prior art references that demonstrated the formulations were predictable.
Infringement
The court determined that Aurobindo’s generic product did not infringe the asserted claims, primarily because the claims covered specific formulations not used in Aurobindo’s product.
Appeal Decisions
The Federal Circuit upheld the district court's invalidity ruling, confirming that the patents did not meet the requirements for patentability due to obviousness and insufficient disclosure.
Market and Patent Strategy Implications
- The outcome reinforced the importance of robust patent prosecution, including detailed enablement disclosures.
- Acorda’s patent portfolio may face increased challenge from generic competitors targeting formulations not sufficiently distinguished.
- The case exemplifies the risk of patent invalidation based on prior art references and the importance of maintaining a strong non-obviousness argument.
Key Takeaways
- The ruling clarifies boundaries for patent claims relating to formulation patents in the pharmaceutical sector.
- Validity challenges through prior art can succeed if formulations are deemed predictable.
- Patent infringement claims hinge on claim scope; narrow claims may limit infringement allegations.
- Strategic patent drafting should focus on non-obvious innovations and comprehensive enablement.
FAQs
1. Why was Acorda’s patent invalidated?
The patents were invalidated primarily due to obviousness based on prior art references and insufficient disclosure that failed to enable the claimed invention.
2. How did the case impact Aurobindo’s entry into the market?
The court’s rulings allowed Aurobindo to launch its generic product following the invalidity of the asserted patents.
3. Can patent claims be designed to avoid invalidity?
Yes, claims that emphasize novel, non-obvious aspects with detailed disclosures are less susceptible to invalidity challenges.
4. What lessons can patent holders learn from this case?
Ensure patent applications include thorough disclosures and claim scopes that clearly differentiate from prior art to withstand validity challenges.
5. Does this case affect future patent litigation for pharmaceutical formulations?
Yes, it underscores the heightened scrutiny of claims covering predictable formulations and the importance of comprehensive patent prosecution strategies.
References
- U.S. District Court for the District of Delaware. (2017). Acorda Therapeutics Inc. v. Aurobindo Pharma Ltd., Case No. 1:14-cv-00909. [Court opinion].
